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This paper evaluates the reasons behind the rise in the use of proton beam for prostate can-
cer,  the economics drivers behind it, and the evidence that exists to support it. It concludes




that clinical outcome data underlying the notion that this is a superior treatment remains
sparse and discusses what is needed to ﬁll in the gaps.
©  2013 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All
rights reserved.
sive that, at current rates of US reimbursement, a hospital1.  Introduction  and  rationale
The properties of the proton beam have been long recognized
as having therapeutic potential. In particular, their singular
property of slowing rapidly in tissue, depositing energy at
depth, and without any dose beyond the target, were envi-
sioned to have great clinical advantage. This was ﬁrst recog-
nized in the 1940s and has been the basis of its use ever since.1
Early therapeutic facilities were merely physics laboratories at
universities cleverly adapted to allow patient treatment. The
beam energies were generally low and so treatment was lim-
ited to tumors at relatively shallow depth such as the eye, the
spine, or the base of skull. In the realm of pediatrics where
low dose, or indeed any dose, radiation to normal tissues can
have disastrous consequences proton beam was used with
enthusiasm. Luckily the lower energy beams then available
had sufﬁcient penetration to reach most pediatric sarcomas
or CNS tumors and indeed tumors almost anywhere in a baby.
In the 1990s patient-dedicated proton facilities were devel-
oped and since then their use and establishment has greatly
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which are fully functional in the Unites States. Contracts
have been signed on many  more  facilities and construction is
underway. It is the wave  of the future and, at current costs,
a very expensive wave.  The enthusiasm, based upon sim-
ple dosimetric studies, has actually preceded the results of
prospective clinical studies designed to assess the outcomes of
this therapy and, in some cases, has actually replaced it. Data
is starting to emerge demonstrating clear advantages in terms
of organ function and a reduction in second malignancies
among the pediatric population.2–4 This has retrospectively
justiﬁed its use in an area where it was long presumed to be
advantageous. The problem is that, in the USA at least, 80%
of patients treated with proton beam have prostate cancer.5
The reasons are simple. Between 3 and 5 prostate patients
can be treated in the time it takes to treat a single complex
pediatric case. The installation of a proton facility is so expen-can only begin to cover its debt with a high throughput of
prostate cancer cases. This has lead to a dangerous distor-
tion of patterns of care. Many centers that should be treating





















































breports of practical oncology and 
hildren treat prostate cancer cases, and many  elderly patients
ith prostate cancer who should be having no treatment at
ll receive it unnecessarily. An “arms race” has begun with
any  centers taking a huge ﬁnancial and moral  risk invest-
ng in proton therapy to keep up with their competitors.6 As
rostate cancer is the US economic engine for proton ther-
py it is worth spending some time assessing the evidence
upporting its use.
.  Uncertainties  in  the  physics  and  biology
he Bragg Peak has a tremendous therapeutic appeal but
n vivo the distribution of the proton beam is subject to many
erturbations and uncertainties. The deeper the beam in tis-
ue the less certain one is of its stopping point. This “end of
ange uncertainty” means that the beam has to be planned
o overshoot the target to guarantee good coverage. In addi-
ion, at greater depths there is considerable lateral scattering
esulting in a signiﬁcant penumbra making the lateral mar-
ins of the beam less sharp.7 Proton beam, like other forms of
article therapy, is highly subject to tissue inhomogeneities.
roﬁmov et al. have demonstrated the difference that small
ovements of the hips can make to a lateral beam delivered
o the prostate.8
The Radio-Biologic Effect of the proton beam has been mea-
ured at 1.1 relative to X-rays yet this number may not be so
recise. Just beyond the Bragg Peak it may be a little higher.
urthermore the RBE may differ slightly for different tissues.
hile this would not matter at lower doses when one is giving
lose to 80 Gy to a prostate, for example, small differences in
BE can be critical. A passively scattered proton beam, and this
emains the prevalent delivery technique in 2013, also gen-
rates neutrons in the collimator with a very high RBE and
 completely unknown contribution to the effect on normal
issues.
Many  of these issues will either be clariﬁed by future exper-
mentation or modeling (RBE) or by moving to spot scanned
eam techniques (neutrons) but, for now they may or they
ay not contribute to the morbidity of proton therapy or, at
east, dilute the beneﬁts.9,10
.  The  clinical  evidence
he management of localized prostate cancer has been con-
roversial for decades. It has been difﬁcult to decide whether
r not any treatment is better than simple observation and, if
o, which of the curative therapies is superior: surgery, exter-
al radiation, or brachytherapy. Among the radiation options
ew technologies have been readily adopted although there is
emarkably little evidence of the beneﬁt they bring. 3-D exter-
al radiation was shown to reduce rates of radiation proctitis
ver simple 2-D therapy.11 In the early 2000s IMRT became
xtremely popular and is now almost exclusively the external
eam strategy of choice in the US. A recent analysis of RTOG
ata suggests that the advantage of IMRT  over 3-D in terms
f morbidity and quality of life may be remarkably small.12
t is impossible to turn back the clock but if this data had
een available over a decade ago it is possible that the bigtherapy 1 8 ( 2 0 1 3 ) 338–342 339
switch to IMRT may have been slowed or, had there been
no ﬁnancial drivers, stopped altogether. New techniques of
image-guidance may ultimately prove to be more  signiﬁcant
than either the planning or beam delivery technique.
Convincing data now exists in the form of ﬁve random-
ized trials demonstrating that higher radiation doses are more
likely to reduce the risk of prostate cancer recurrence and,
in the case of high-risk tumors, the rate of metastases.13,14
This now drives the use of high-doses in practice with the
presumption that only IMRT  or proton beam are adequate to
safely them. High quality evidence demonstrating that that
is the case is indeed rare. At the end of the day the highest
radiation doses are delivered by brachytherapy, a low cost and
thus high-value alternative. Quality of life studies have failed
to show that patients receiving brachytherapy fare any worse
than those receiving any form of high-tech external beam
treatment.15
One randomized trial has compared proton beam with con-
ventional radiation and showed no difference in any outcome.
Interpretation of this study is, however, greatly limited by the
fact that it treated advanced cases who would have been bet-
ter served by the addition of hormonal therapy and because it
took place in the pre-PSA era when many  patients would have
had occult metastatic disease at the time of presentation.16
The work of the Massachusetts General Hospital has tested
a number of hypotheses:
Does proton beam produce superior dose distributions over IMRT
for prostate cancer? The answer is mixed. There is undoubt-
edly less of a “dose bath” to the anterior and posterior tissues
but more  radiation passes through the femoral heads and,
because of beam uncertainty, the high-dose volume is actu-
ally a little larger with protons than IMRT17 Fig. 1. In addition,
two regions associated with morbidities (the prostatic urethra
and peri-prostatic nerve bundles) are treated equally with the
two techniques. The volume of rectum treated likely depends
more  on image  guidance, choice of margins, and the use or
not of a rectal balloon than it does the delivery technique.
Does proton beam cure patients with prostate cancer? Indeed
it does, as do all forms of radiation delivered in high dose. A
prospective phase III study clearly shows that doses of 79 Gy
can be delivered safely with protons and that over 90% of low-
risk patients may be cured this way. The problem is that 79 Gy
can also easily be delivered by IMRT  and probably by 3-D ther-
apy also.18 A case-controlled study has also shown that the
cure rates at 10 years from proton beam and brachytherapy
appear to be identical19 Fig. 2.
Can proton beam be used to dose escalate further? This has been
tested in a phase II study of 90 patients. 82 Gy was delivered but
unacceptable levels of rectal toxicity were reached implying
that, for whole gland treatment using current techniques at
least, 79 Gy is close to the practical limit.20
Can proton beam be used to escalate the dose further to part
of the prostate gland? It is certainly appealing to imagine the
entire gland being treated to one dose and a dominant nodule
being treated to a higher dose. This could represent intelligent
dose escalation without morbidity escalation and is theoret-
ically possible using scanned beam techniques. The problem
is that our imaging, although improving, rapidly, is currently
insufﬁcient to pick out a target within the prostate with great
reliability. In addition our techniques of image-guidance and
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Fig. 1 – Comparative planning study showing the difference in dose distribution between opposed lateral, passively
 planscattered proton beams and an intensity modulated photon
prostate immobilization may not yet be sufﬁciently reliable to
allow us to sharp shoot in this manner.
Does proton beam reduce the morbidity of prostate treatment?
This is, perhaps, the most important question of all. If it
does then the size of the effect can be measured against the
cost of the therapy and policy decisions about its value be
made. Talcott et al. have performed some prospective and
other cross-sectional quality of life studies on prostate cancer
patients receiving proton beam therapy as well as IMRT and
3-D. The ﬁrst item of note is that there is indeed signiﬁcant
sexual, bladder, and rectal dysfunction among patients after
proton beam. While any treatment that covers the nerves,
prostatic urethra, bladder neck, and anterior rectum would be
expected to have these consequences somehow the “internet
hype” around proton beam suggests that this is never the case.
When the late effects (5–10 years) are measured against 3-D
and IMRT  few differences can be seen.21 A recent study by Efs-
tathiou et al. suggests that there may be a small reduction in
Fig. 2 – Case-controlled study from the Massachusetts
General Hospital comparing patients treated with either
high-dose proton beam radiation or low dose-rate
brachytherapy. Figure shows cumulative biochemical
recurrence rates.19.
proctitis during the ﬁrst post-treatment year but this is a sin-
gle study and the effect was small and temporary.22 New data
emerging from other US proton centers certainly show excel-
lent (though non-comparative) quality of life-outcomes.23
Whether this is the result of the proton beam or the techniques
of image-guidance adopted in parallel remains unclear.
A highly controversial study was recently published which
used the SEER database to assess the late consequences of
different types of external radiation therapy measuring the
outcomes using billing codes for interventions such as cys-
toscopy, colonoscopy, or argon plasma coagulation.24 The data
appeared to show that, for the time interval studied, the rectal
morbidity of proton beam was actually higher than photons.
There are many  weaknesses in this kind of study, one that
does not use information gathered directly from patients and
which preceded the era of image-guidance, but it certainly
does make the case that the superiority of proton beam can-
not be presumed in every situation. It is possible that some of
the current physical and biological uncertainties are indeed
limiting.
4.  Cost  considerations
It is the cost of proton beam therapy that makes its use in
prostate cancer, when there are many  alternatives, so contro-
versial. In the USA the price charged and the reimbursement
delivered vary greatly from one insurer to another and from
one state to the next and so the reimbursement for almost
all forms of treatment ﬂuctuate considerably. It is, however,
generally agreed that the cost of proton treatment is greater
than that of IMRT,  which is, in turn, greater than brachyther-
apy, surgery, or active surveillance. Brachytherapy and active
surveillance are generally agreed to be the “best bargains”.
Many modeling studies have been performed which attempt
to determine the value of proton therapy but most make
assumptions about beneﬁt which are, as was seen in the previ-
ous sections, somewhat shaky. One particular modeling study
made the assumption that an additional 10 Gy could be safely
delivered by proton beam pushing the delivered dose to 91 Gy
and that this would lead to a small but detectable survival
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ife saved (quality adjusted life years) was prohibitively high.
s has been shown both these assumptions were incorrect
nyhow.
The cost of proton beam remains very ﬂuid especially in
n era of cost control and health care reform and no-one
s yet clear what direction prices are heading. There are,
owever, two changes on the horizon that will likely change
he cost equation in some fashion. The ﬁrst is that hypo-
ractionated radiation is emerging as a convenient lower-cost
ethod of administering external beam with high-level phase
II support. It is possible that the homogeneity of the pro-
on beam is better suited to large doses per fraction than
he less homogeneous IMRT.  Even so, other photon platforms
or delivering these fractions with high accuracy now exist. If
ypo-fractionation becomes the norm then proton beam will
lso become more  competitive in terms of price.
A second trend is the development of smaller single-gantry
roton facilties. Johnstone et al. have calculated that the debt
ncurred is easier to recuperate with a smaller proportion of
rostate cases.5 With further technological advances it is likely
hat the cost differential between protons and photons will, in
ime, diminish.
.  Proton  treatment  for  prostate  cancer  in
he  future
rostate cancer treatments have, to date, largely employed
pposed lateral beams because the end-of-range uncertainty
as made overshooting of the target necessary. Any beam
ngled toward the anterior would thus enter the rectum in an
ndesirable way. Unfortunately, lateral beams have to take the
ongest route to the prostate possible and must pass through
he inhomogeneous and mobile hips. It has been said that
n this scenario we  are taking an advanced technology and,
rankly, getting the least out of it. It is clear that the tech-
ology will not stand still and the development of scanned
roton beams with their ability to be modulated should fur-
her increase the conformality of the proton beam in the near
uture allowing more  creative beam angles and target shap-
ng. The advantage of IMRT  in that it can scoop out a hollowed
olume on the rectal side of the prostate will be mimicked
nd perhaps exceeded, by intensity modulated protons. Par-
ial prostate boosting may become more  of a technical reality
ith scanned beams if imaging can improve correspondingly.
Much  of the controversy over prostate cancer comes from
ts high price tag and much would evaporate if the cost came
own substantially. This is likely to happen but the installa-
ion costs of even a single gantry facility will be greater than
inear accelerators for the forseeable future and treatment
osts will always greater than simple brachytherapy or active
urveillance because of the high stafﬁng and maintenance lev-
ls required. Thus, the debate will continue to turn upon the
dvantage patients (or payers) are receiving for the additional
ost. As I have shown the evidence so far does not suggest that
his advantage is great but it may still be present at a level that
as been difﬁcult for recent studies to detect. For many  years
he call has been heard for the establishment of a random-
zed trial. The strong arguments against come from those who
eel that the do simetry speaks for itself, that protons cannottherapy 1 8 ( 2 0 1 3 ) 338–342 341
be inferior, and thus an RCT is ethically unjustiﬁable. It also
comes from those who feel that RCTs are simply not the way
to solve technology questions. An RCT for every new technol-
ogy would slow down the engine of technological innovation,
indeed bring it to a halt. Most technologies are simply sharper
knives and where would one draw the line of RCT necessity?
Others feel that the RCT should be used for technology but
rarely and selectively.26 This will be for: new technologies that
are vastly expensive and potentially disrupt the ﬂow of health
care dollars elsewhere; for technologies that potentially intro-
duce new biology and thus may have unpredictable outcomes;
and for technologies that require a great deal of retraining
and recertiﬁcation. Proton beam ﬁts the bill. No-one would
argue for a trial in every clinical scenario. For example, most
would be very uncomfortable randomizing children to proton
beam or IMRT when the IMRT  dose carries such risk. Equally
there would be little value randomizing skin cancers where
no beneﬁt could be anticipated, or perhaps diseases such as
localized lymphomas or plasmacytomas where the radiation
doses are relatively low. Prostate cancer ﬁts into a gray zone of
high use and high cost but unpredictable outcomes. If nothing
else an RCT would quantify the beneﬁt, if there is any, which
could be used to inform the debate, and drive rational policies.
The same is also true of proton beam in lung cancer where
the unpredictable behavior of proton beam across air cavities
makes the ultimate outcome uncertain.
Despite the media and internet hyperbole patients do
appear willing to participate in such a trial for prostate cancer
and several major US proton centers led by the Massachusetts
General Hospital and University of Pennsylvania have recently
launched a phase III study comparing proton beam against
IMRT for localized low and low-intermediate risk prostate
cancer (http://clinicaltrials.gov/ct2/show/NCT01617161), with
patient-reported quality of life outcomes, as well as other clin-
ical, physical, biological, and economic end-points. It is hoped
that the results of this trial will come before the landscape
of prostate cancer treatment has been changed in a dramatic
and, perhaps needless, fashion.
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